Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

GSK, INNOVAX and Xiamen University to jointly develop cervical cancer vaccine

Xinhua | Updated: 2019-09-07 14:26
Share
Share - WeChat
The logo of GlaxoSmithKline (GSK) is seen on its office building in Shanghai. [Photo/Agencies]

BRUSSELS - INNOVAX, a subsidiary of China's YangShengTang Group, and Xiamen University signed a global alliance partnership agreement on Friday with British pharmaceutical giant GlaxoSmithKline (GSK) in Wavre, Belgium, to develop a next-generation vaccine against human papillomavirus (HPV).

Zhong Shanshan, chairman of YangShengTang Group, announced this in an interview with Xinhua.

This vaccine will combine the innovative antigen detection method developed by Prof Xia Ningshao's team at Xiamen University, with GSK's proprietary adjuvant AS04, which leverages this antigen technology.

Shazia Sheikh, director of public affairs for global and emerging markets at GSK Vaccine, confirmed the news via email on Friday.

Zhong stressed that this is the first time a Chinese vaccine company, by leveraging its original technology, has entered into a partnership with a world leading vaccine company to co-develop and ultimately commercialize an important vaccine globally. This alliance shows that China's vaccine technology has been highly regarded by its international counterparts. And the partnership is an exemplary collaboration between the pharmaceutical industries of China and Europe.

Zhang Rong, president of Xiamen University, told Xinhua that biological research at Xiamen University has a history of nearly one hundred years. Making scientific and technological achievements that are beneficial to human health and wellbeing and promoting their commercialization is consistent with the University's mission.

"This partnership is a milestone in the past 20 years of industry-research collaboration between INNOVAX and Xiamen University. It is also a commercial cooperation between a Chinese vaccine company and a global vaccine company from Europe. But, above all, it is a model of how the international academic and industrial community can join hands to fight human diseases," he added.

Under the agreement, INNOVAX will build a vaccine production line in Xiamen, Southeast China, that will comply with the standards set by China, the United States, the European Union and the World Health Organization. It will produce and provide to GSK various types of HPV vaccine antigens, which will then be combined with GSK's patented AS04 adjuvant to develop new HPV vaccines for worldwide commercialization, including in Europe and the United States.

GSK said the partnership with INNOVAX will accelerate the development of the next generation of its cervical cancer vaccine.

According to Zhong, the antigen technology was born in the joint biopharmaceuticals laboratory of Xiamen University and YangShengTang led by Professor Xia. It successfully used DNA recombination technology to express proteins in E coli and used it for vaccine production. INNOVAX's cervical cancer vaccine is highly effective in that it protects more HPV types with fewer virus-like particles (VLPs).

The bivalent cervical cancer vaccine co-developed by INNOVAX and Prof. Xia's team is the first Chinese cervical cancer vaccine that has completed the Phase III clinical trial. Commercialization of this vaccine will make China the world's third country with the ability to independently manufacture cervical cancer vaccines after the US and the UK. GSK accelerated partnership talks between the two parties in November, 2018, when INNOVAX's Phase III clinical trial data on cervical cancer vaccine were released.

The cervical cancer vaccine has broad market prospects globally. Cervical cancer is the third most common cancer in women. It is estimated that every year 311,365 women are killed and in every two minutes, a woman will die of cervical cancer. Almost all cases of cervical cancer are caused by the human papillomavirus (HPV). Over 100 types of HPV virus are known, and over 15 of them can cause cervical cancer.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 久久综合琪琪狠狠天天| 6080一级毛片| yellow高清在线观看完整视频在线 | 综合欧美日韩一区二区三区| 伊人影院中文字幕| 亚洲人成伊人成综合网久久久| 亚洲欧美校园春色| 激情网站免费看| 色综合久久天天综合| 精品午夜福利在线观看| 污网站免费观看污网站| 欧洲成人爽视频在线观看| 日本三级在线观看免费| 好男人在线视频www官网| 国产精品麻豆免费版| 国产午夜无码福利在线看网站| 午夜天堂在线观看| 亚洲欧美日韩中文字幕一区二区三区 | 人人妻人人澡人人爽精品欧美| 亚洲精彩视频在线观看| 亚洲va在线∨a天堂va欧美va| 久久久久人妻一区精品色| chinese激烈高潮HD| 91香蕉视频直播| 男同免费videos欧美| 最近中国日本免费观看| 女人是男人的未来视频| 国产成人无码av片在线观看不卡| 免费在线观看视频| 久热中文字幕在线精品免费 | 日韩欧美亚洲精品| 妞干网在线播放| 国产手机在线播放| 免费午夜扒丝袜www在线看| 五月天六月丁香| jizzjizz之xxxx18| 青青草97国产精品免费观看| 波多野结衣办公室在线观看| 日本污全彩肉肉无遮挡彩色| 国内精品久久久久久久久齐齐| 国产一区二区在线视频|